Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAG: Fulvestrant vs Anastrozole with Goserelin in Premenopausal Breast Cancer
NCT01266213Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Dec 2010
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant in breast cancer (3 arms), sponsored by Samsung Medical Center. Primary endpoint: Time to Progression. Status: unknown.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01266213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266213.